On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Releases Stockholder Letter

Company: 180 Life Sciences Corp. (ATNF)
Category: News

180 Life Sciences Corp. (NASDAQ: ATNF) CEO James Woody, MD, PhD, has issued a letter to ATNF stockholders. In the letter he provides an overview of the company’s activities and accomplishments since his last stockholder letter, which was released in November 2020. The letter noted the company’s achievement in both legacy-related issues and strengthening its balance sheet. A highlight mentioned in the letter was that the company had reduced its debt from $5 million to $316,000. Woody also reported that the company had converted $3 million in preferred equity to equity. In the letter, Woody also noted that the company had added two new members to its board of directors and was in the process of adding two additional independent directors to its board, which would bring ATNF in compliance with NASDAQ’s continued listing requirements. The letter also highlighted 180 Life Sciences exciting pipeline, including its three clinical programs: Early Dupuytren’s contracture, a fibrotic disease of the hand; frozen shoulder; and post-operative cognitive delirium disorder and dysfunction, a major unmet clinical need occurring in the elderly patient population. “At 180 Life Sciences, we continue to move forward on all fronts. Including efforts to increase visibility for our team and its mission. We are proactively working on telling our story through a steady flow of participation in investor conferences, thought leadership opportunities through earned media, and continued amplification through social media channels,” wrote ATNF CEO James Woody in the letter. “It is important to note that our business model itself is unique for a biotech company. Almost all our clinical studies to date have been funded in full through grants. While ultimately, we intend to fund some studies internally, we anticipate our operating expenses will remain low relative to our peers. There are many advantages of doing clinical development mostly with academic leaders, both in cost, efficiency and credibility.”

To view the full press release, visit https://nnw.fm/5OU3t

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://nnw.fm/ATNF

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217